Life science company Beckman Coulter Life Sciences stated on Thursday that its RNA extraction kit, RNAdvance Viral XP, has been included on the list of acceptable extraction methods for use in the Centers for Disease Control's EUA-authorized COVID-19 test referenced in the FDA's FAQ on testing for SARS-CoV-2.
The company explained that the extraction of RNA from viral samples is a critical step for pathogen research and detection to enable accurate downstream assay results. Laboratories are now permitted to independently validate RNAdvance Viral XP for use.
Earlier this month the company formally launched RNAdvance Viral XP as a reagent kit for research use.
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment